间歇扫描式持续葡萄糖监测与自我血糖监测在近期急性心肌梗死合并2型糖尿病患者中的多中心随机试验:LIBERATES试验结果
LIBERATES多中心随机试验纳入141例近期心肌梗死且住院前使用胰岛素和/或磺脲类药物的2型糖尿病患者,比较间歇扫描式持续葡萄糖监测(isCGM)与自我血糖监测(SMBG)。主要结局为随机化后第76-90天葡萄糖3.9-10 mmol/L范围内时间(TIR),isCGM组TIR增加17分钟/天(95%可信区间-105至+153分钟/天),获益概率59%;isCGM组低血糖暴露(<3.9 mmol/L)在第76-90天减少80分钟/天(95%CI -118,-43),两组HbA1c均降低7 mmol/mol,isCGM具成本效益。
要点
- isCGM组TIR较SMBG组增加17分钟/天(95%可信区间-105至+153),获益概率59%。
- isCGM组第76-90天低血糖暴露(<3.9 mmol/L)较SMBG组减少80分钟/天(95%CI -118,-43)。
- 两组HbA1c较基线均降低7 mmol/mol,isCGM具成本效益。
核心结论
- 在近期心肌梗死合并2型糖尿病患者中,与SMBG相比,isCGM轻度增加TIR并显著减少低血糖暴露,同时同等改善HbA1c,解释了其成本效益;需要研究这些血糖差异是否转化为长期临床获益。
研究设计与样本
- LIBERATES为多中心两臂随机试验,比较SMBG与isCGM在近期心肌梗死且住院前使用胰岛素和/或磺脲类药物的2型糖尿病患者中的应用,共141例参与者随机分配,中位年龄63岁(四分位距53,70),其中73%为男性。
主要发现
- isCGM组TIR较SMBG组增加17分钟/天(95%可信区间-105至+153分钟/天),获益概率59%。
- isCGM组第76-90天低血糖暴露(<3.9 mmol/L)较SMBG组减少80分钟/天(95%CI -118,-43),第16-30天也可见(-28分钟/天;95%CI -92,2)。
- 两组HbA1c较基线在3个月时均降低7 mmol/mol。
- isCGM组4例、SMBG组7例发生合并血糖急症和死亡。
- 生活质量指标 marginal 倾向于isCGM,且该干预具成本效益。
关键数值与推荐
- 主要结局为随机化后第76-90天葡萄糖3.9-10 mmol/L范围内时间(TIR)。
- isCGM组TIR增加17分钟/天(95%可信区间-105至+153分钟/天),获益概率59%。
- isCGM组第76-90天低血糖暴露(<3.9 mmol/L)减少80分钟/天(95%CI -118,-43)。
- 两组HbA1c较基线均降低7 mmol/mol。
局限性
- 需要研究以了解这些血糖差异是否转化为长期临床获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To analyze the impact of modern glucose-monitoring strategies on glycemic and patient-related outcomes in individuals with type 2 diabetes (T2D) and recent myocardial infarction (MI) and assess cost effectiveness. RESEARCH DESIGN AND METHODS: LIBERATES was a multicenter two-arm randomized trial comparing self-monitoring of blood glucose (SMBG) with intermittently scanned continuous glucose monitoring (isCGM), also known as flash CGM, in individuals with T2D and recent MI, treated with insulin and/or a sulphonylurea before hospital admission. The primary outcome measure was time in range (TIR) (glucose 3.9-10 mmol/L/day) on days 76-90 post-randomization. Secondary and exploratory outcomes included time in hypoglycemia, hemoglobin A1c (HbA1c), clinical outcome, quality of life (QOL), and cost effectiveness. RESULTS: Of 141 participants randomly assigned (median age 63 years; interquartile range 53, 70), 73% of whom were men, isCGM was associated with increased TIR by 17 min/day (95% credible interval -105 to +153 min/day), with 59% probability of benefit. Users of isCGM showed lower hypoglycemic exposure (<3.9 mmol/L) at days 76-90 (-80 min/day; 95% CI -118, -43), also evident at days 16-30 (-28 min/day; 95% CI -92, 2). Compared with baseline, HbA1c showed similar reductions of 7 mmol/mol at 3 months in both study arms. Combined glycemic emergencies and mortality occurred in four isCGM and seven SMBG study participants. QOL measures marginally favored isCGM, and the intervention proved to be cost effective. CONCLUSIONS: Compared with SMBG, isCGM in T2D individuals with MI marginally increases TIR and significantly reduces hypoglycemic exposure while equally improving HbA1c, explaining its cost effectiveness. Studies are required to understand whether these glycemic differences translate into longer-term clinical benefit.
引用
- Ajjan RA, Heller SR, Everett CC, et al. Multicenter Randomized Trial of Intermittently Scanned Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in Individuals With Type 2 Diabetes and Recent-Onset Acute Myocardial Infarction: Results of the LIBERATES Trial. Diabetes Care. 2023. PMID: 36516054. doi:10.2337/dc22-1219
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。